Ginkgo Bioworks Holdings (DNA) Cost of Revenue (2020 - 2026)

Ginkgo Bioworks Holdings has reported Cost of Revenue for 7 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 24.25% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$8.9 million (up 40.55% YoY), and the FY2021 full-year result was $20.0 million, up 124.76% from the prior year.
• Cost of Revenue for Q1 2026 stood at $3.1 million, up from -$25.6 million in the prior quarter.
• The five-year high for Cost of Revenue was $77.3 million in Q1 2022, with the low at -$160.8 million in Q4 2022.
• Historically, Cost of Revenue has averaged -$6.4 million across 5 years, with a median of $4.1 million in 2025.
• The largest YoY upside for Cost of Revenue was 678.43% in 2022 against a maximum downside of 3427.79% in 2022.
• Ginkgo Bioworks Holdings' Cost of Revenue stood at -$160.8 million in 2022, then jumped by 70.53% to -$47.4 million in 2023, then surged by 34.6% to -$31.0 million in 2024, then rose by 17.49% to -$25.6 million in 2025, then jumped by 112.11% to $3.1 million in 2026.
• The last three Cost of Revenue figures came in at $3.1 million (Q1 2026), -$25.6 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.